Loading clinical trials...
Loading clinical trials...
Assessment if a Daily SMS (Short Message System) Reminder Improves the Adherence of COPD Patients to Therapy With Spiriva® 18 Microgram
Conditions
Interventions
SMS reminder
control group
Locations
5
Germany
Boehringer Ingelheim Investigational Site 1
Berlin, Germany
Boehringer Ingelheim Investigational Site 2
Cottbus, Germany
Boehringer Ingelheim Investigational Site 3
Hamburg, Germany
Boehringer Ingelheim Investigational Site 4
Koblenz, Germany
Boehringer Ingelheim Investigational Site 5
Lübeck, Germany
Start Date
March 1, 2011
Primary Completion Date
November 1, 2011
Last Updated
January 18, 2013
NCT06831994
NCT02755974
NCT05050591
NCT05913765
NCT05592847
NCT00683722
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions